Supratherapeutic vancomycin levels after trauma predict acute kidney injury and mortality.

[1]  V. Johnson,et al.  Risk of Vancomycin-induced Nephrotoxicity in the Population With Chronic Kidney Disease , 2013, The American journal of the medical sciences.

[2]  D. Paterson,et al.  Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter , 2012, Antimicrobial Agents and Chemotherapy.

[3]  C. Murray,et al.  Serum Vancomycin Levels Resulting From Continuous or Intermittent Infusion in Critically Ill Burn Patients With or Without Continuous Renal Replacement Therapy , 2012, Journal of burn care & research : official publication of the American Burn Association.

[4]  K. Mergenhagen,et al.  The Relationship of Nephrotoxicity to Vancomycin Trough Serum Concentrations in a Veteran's Population: A Retrospective Analysis , 2012, The Annals of pharmacotherapy.

[5]  T. Fabian,et al.  Treatment of methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia with high-dose vancomycin or linezolid , 2012, The journal of trauma and acute care surgery.

[6]  David C. Reynolds,et al.  Performance of a vancomycin dosage regimen developed for obese patients. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[7]  R. Bellomo,et al.  Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: A multicentre pharmacokinetic study* , 2012, Critical care medicine.

[8]  Kent A Stevens,et al.  Influence of the National Trauma Data Bank on the study of trauma outcomes: is it time to set research best practices to further enhance its impact? , 2012, Journal of the American College of Surgeons.

[9]  H. Khalili,et al.  Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review , 2012, European Journal of Clinical Pharmacology.

[10]  R. Kullar,et al.  Effects of Targeting Higher Vancomycin Trough Levels on Clinical Outcomes and Costs in a Matched Patient Cohort , 2012, Pharmacotherapy.

[11]  Marlea G. Wellein,et al.  Relationship between Vancomycin Trough Concentrations and Nephrotoxicity: a Prospective Multicenter Trial , 2011, Antimicrobial Agents and Chemotherapy.

[12]  P. Jorens,et al.  Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients , 2011, Annals of intensive care.

[13]  Julianne Joo,et al.  Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. , 2011, International journal of antimicrobial agents.

[14]  J. Leggett,et al.  Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. , 2010, The American journal of medicine.

[15]  H. Baker,et al.  Incidence, Clinical Predictors, Genomics, and Outcome of Acute Kidney Injury Among Trauma Patients , 2010, Annals of surgery.

[16]  An S De Vriese,et al.  Recent changes in vancomycin use in renal failure. , 2010, Kidney international.

[17]  R. Hall,et al.  Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? , 2010, The American journal of medicine.

[18]  V. Tam,et al.  Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. , 2009, International journal of antimicrobial agents.

[19]  P. Teixeira,et al.  Methicillin-Resistant Staphylococcus Aureus in a Surgical Intensive Care Unit , 2009, The American surgeon.

[20]  B. Erstad,et al.  Vancomycin dosing for pneumonia in critically ill trauma patients. , 2009, The Journal of trauma.

[21]  G. Drusano,et al.  Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Rello,et al.  Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? , 2008, Current opinion in critical care.

[23]  V. Tam,et al.  Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. , 2008, The Journal of antimicrobial chemotherapy.

[24]  K. Stellrecht,et al.  Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin , 2008, Antimicrobial Agents and Chemotherapy.

[25]  G. Drusano,et al.  Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity , 2008, Antimicrobial Agents and Chemotherapy.

[26]  Joshua A. Doherty,et al.  A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. , 2007, Clinical therapeutics.

[27]  K. Raghavendran,et al.  Predictive value of sputum gram stain for the determination of appropriate antibiotic therapy in ventilator-associated pneumonia. , 2007, The Journal of trauma.

[28]  A. Wong-Beringer,et al.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. , 2006, Archives of internal medicine.

[29]  M. Rybak,et al.  Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. , 2005, Chest.

[30]  S. Cosgrove,et al.  The Impact of Methicillin Resistance in Staphylococcus aureus Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges , 2005, Infection Control & Hospital Epidemiology.

[31]  E. Armstrong,et al.  Clinical and Economic Analysis of Methicillin-Susceptible and -Resistant Staphylococcus aureus Infections , 2004, The Annals of pharmacotherapy.

[32]  T. Perl,et al.  Staphylococcus aureus with reduced susceptibility to vancomycin. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  G. Eliopoulos,et al.  Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia , 2004, Journal of Clinical Microbiology.

[34]  H. Chambers,et al.  Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods , 2003, Antimicrobial Agents and Chemotherapy.

[35]  S. Cosgrove,et al.  Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  T. Fabian,et al.  Antibiotic pharmacokinetics following fluid resuscitation from traumatic shock. , 1995, Archives of surgery.

[37]  J. Ramirez,et al.  Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. , 2012, Clinical therapeutics.

[38]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[39]  S. Cosgrove,et al.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.